New mRNA vaccine targets Epstein-Barr virus in first human trial

NCT ID NCT07557602

Not yet recruiting ⭐️ VACCINE ⭐️ Sponsor: Vaccine Company, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new mRNA vaccine called VXCO-102 against Epstein-Barr virus (EBV) in 45 healthy adults aged 18 to 25. The main goal is to check if the vaccine is safe and triggers an immune response. EBV is a common virus that can cause mononucleosis and is linked to some cancers, so a successful vaccine could have a big impact.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: VXCO-102 (mRNA vaccine targeting Epstein-Barr virus)
What this could lead to: If successful, this could pave the way for a vaccine to prevent EBV infection, which is linked to mononucleosis and certain cancers.
What could go wrong: This is an early Phase 1 trial with only 45 participants, so it is primarily testing safety, not effectiveness. The vaccine may not produce a strong immune response or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EBV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Epstein-Barr virus infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EBV

Contacts and locations

Locations

Nucleus Network Pty Ltd

Melbourne, Victoria, 3004, Australia
Q-Pharm Pty Ltd/Nucleus Network Pty Ltd

Herston, Queensland, 4006, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.